scholarly journals A Case of Hepatic Metastases of Gastric GIST Successfully Treated with Imatinib Mesylate

2006 ◽  
Vol 55 (5) ◽  
pp. 173-178
Author(s):  
Hiroaki TAKENAKA ◽  
Takaharu YAGI ◽  
Toshiki TANAKA ◽  
Masahiko ORITA ◽  
Nobuyoshi MORITA ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Hepatic Metastases ◽  
Gastric Gist

scholarly journals A Case of Liver Metastasis from Gastric GIST Resected after Imatinib Mesylate Therapy

2020 ◽  
Vol 81 (9) ◽  
pp. 1780-1785
Author(s):  
Yosuke MORIMOTO ◽  
Koji FUJITA ◽  
Hiroyuki KIKUNAGA ◽  
Hiroshi MIURA ◽  
Syojiro MORINAGA ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Imatinib Mesylate ◽  
Gastric Gist

scholarly journals Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate

2013 ◽  
Vol 70 (2) ◽  
pp. 225-228 ◽  
Author(s):  
Radoje Colovic ◽  
Marjan Micev ◽  
Slavko Matic ◽  
Natasa Colovic ◽  
Nikica Grubor ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Imatinib Mesylate ◽  
Left Lobe ◽  
Uneventful Recovery ◽  
Gastrointestinal Neoplasms ◽  
Gastric Gist ◽  
Tissue Samples ◽  
Billroth Ii Gastrectomy ◽  
Cystic Liver ◽  
The Right

Introduction. Gastrointestinal stromal tumors (GISTs) are rare and account for 0.1%-3% of all gastrointestinal neoplasms. GISTs are most commonly located in the stomach (60%) and 20%-25% are malignant, with metastases involving the peritoneum or the liver. Cystic liver metastases are extremely rare. Only two previous cases of patients with cystic liver metastases, prior to treatment with imatinib mesylate, have been described so far. Case report. We reported a 52-year-old woman presented with a history of abdominal fullness and discomfort. Clinical examination revealed two palpable masses, first in the right upper abdomen and second left to the umbilicus. Examinations revealed 4 cystic metastases in the liver, 3 in the right lobe (including a huge one measuring 20.5 x 16 cm), and 1 in the left lobe, together with a primary tumor on the greater curvature of the stomach. Gastric tumor was removed with a Billroth II gastrectomy. Partial excision of the largest liver metastasis was performed for histopathology. Immunohistochemistry confirmed the diagnosis of a GIST in both tissue samples. After an uneventful recovery the patient was commenced on imatinib mesylate therapy. The patient remainsed symptom-free at 24 months follow-up. Conclusion. This was the third reported case of gastric GIST with giant cystic liver metastases present prior to treatment with imatinib mesylate. Although extremely rare, GISTs may present with cystic liver metastases prior to treatment with imatinib mesylate, and should be considered in the differential diagnoses of patients with liver cysts of uncertain aetiology.

scholarly journals A CASE OF LIVER METASTASIS OF GASTRIC GIST RESECTED AFTER ADMINISTRATION OF IMATINIB MESYLATE

2007 ◽  
Vol 68 (2) ◽  
pp. 415-419 ◽  
Author(s):  
Kazuhiro MIGITA ◽  
Akihiko WATANABE ◽  
Chihiro SAKAMOTO ◽  
Takao OHYAMA ◽  
Hirofumi ISHIKAWA ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Imatinib Mesylate ◽  
Gastric Gist

scholarly journals A Large Gastric GIST with Peritoneal Dissemination Who Underwent Surgery to Control Infection Due to Abscess Formation during Imatinib Mesylate Therapy

2017 ◽  
Vol 50 (5) ◽  
pp. 350-356
Author(s):  
Jongsung Pak ◽  
Kazuyoshi Yamamoto ◽  
Kazuhiro Nishikawa ◽  
Motohiro Hirao ◽  
Masakazu Miyake ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Peritoneal Dissemination ◽  
Abscess Formation ◽  
Gastric Gist ◽  
Control Infection

scholarly journals Gastrointestinalni tumor zeluca (GIST) kao uzrok masivnog krvarenja iz gornjih partija digestivnog trakta

2007 ◽  
Vol 54 (1) ◽  
pp. 169-171 ◽  
Author(s):  
V.R. Djukic ◽  
A.R. Karamarkovic ◽  
S. Mijatovic ◽  
M. Micev ◽  
V.M. Bumbasirevic ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Imatinib Mesylate ◽  
Kinase Inhibitor ◽  
Complete Response ◽  
Response To Treatment ◽  
Gastric Gist ◽  
Adjuvant Imatinib ◽  
Mesenchymal Tumors ◽  
Promising Treatment ◽  
Histopathology Examination

Gastrointestinal stromal tumors GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by expression of a receptor that activates tyrosine kinase called C- kit. Since malignant GIST has an extremely poor prognosis even after surgical resection. The development of a tyrosine kinase inhibitor, STI571/imatinib mesylate/Gleevec, Glivec which inhibits the BCR-ABL, PDGF-R alpha, and C-Kit receptors, has changed the management of unrespectable malignant GIST and has improved the survival of patients with metastaic disease. We report a 32 year old male patient with subcardiale gastric GIST and massive gastrointestinale bleeding. The patient underwent total gastrectomy, D2 lymphadenestomy, distal pancreatectomy and splenectomy on 02.02. 2004. Histopathology examination of the primary tumor revealed a strong C-Kit expression and CD 34 +++, Ki67 20 and so called "Pure GIST" was approved Liver metastasis was detected on ultrasound and CT 12 months later and segmentectomy S7 was performed on 23.03.2005. Postoperative course was uneventful. HP examination - malignant 35 x 30 mm sarcoma like tumor of mesenchymal origin. The patient received adjuvant imatinib -mesylate Gleevec Novartis Pharma Basel 400 mg a day. The initial complete response to treatment continued to 24 months postoperatively Imatinib is a recent and very promising treatment extirpation remains the only curative treatment of malignant GIST as evidenced by our patient.

scholarly journals A CASE OF LAPAROSCOPIC SPLENECTOMY FOR LOCAL RECURRENCE OF GASTRIC GIST AFTER TREATMENT WITH IMATINIB MESYLATE

2007 ◽  
Vol 68 (9) ◽  
pp. 2229-2232 ◽  
Author(s):  
Keisuke KOEDA ◽  
Akira SASAKI ◽  
Hisataka FUJIWARA ◽  
Masanori TAKAHASHI ◽  
Takehiro CHIBA ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Imatinib Mesylate ◽  
Laparoscopic Splenectomy ◽  
Gastric Gist
Sign in / Sign up

Export Citation Format

Share Document